Moreover, their research on −174G/C polymorphism of the IL-6 gene and obesity in relation to the therapeutic response to TNF-α blockers showed that the polymorphism can be considered a risk factor in the prognosis of psoriasis treatment. The gene discussed is TNF; the disease is obesity due to melanocortin 4 receptor deficiency.